HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Groups Seek Hill Champions For DSHEA Defense in 2014

This article was originally published in The Tan Sheet

Executive Summary

A top legislative priority for the supplement industry in 2014 is developing congressional champions who can help it defend DSHEA, navigate potential labeling legislation, push for coverage under health savings accounts and meet other goals.

You may also be interested in...



US Rule For Mandatory Supplement Registration Would Likely Give FDA Authority For Fines

“We would certainly want to have some enforcement and be able to utilize that enforcement,” says ODSP acting director Cara Welch. Stakeholders opposed to the change should “get comfortable with the idea of opening up DSHEA and should most certainly be part of the discussion.”

FSA/HSA Coverage Tops CHPA 2014 Legislative Goals

The Consumer Healthcare Products Association’s No. 1 legislative priority in 2014 is restoring OTC coverage by flexible spending and health savings accounts, followed by a “close No. 2” goal of establishing an age requirement to buy DXM products. Other goals include protecting access to PSE products and blocking take-back programs.

In Brief: Acetaminophen Warnings, OTC HSA Bill, Durbin’s Supplement Reg Bill

FDA adds acetaminophen warnings; CHPA suggests 4-aminophenol standard; OTC HSA bill in House; supplement registration bill reintroduced; FSMA user fees still on hold; more scrutiny of energy drinks; and Public Citizen pans OTC Oxytrol.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS139314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel